Kiniksa Pharmaceuticals International Plc (KNSA) Stock Price, Quote & News

Company Profile

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clin...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 44 78 1431 9100

Website: www.kiniksa.com

Address:

105 Piccadilly, 2nd Floor, London, United Kingdom

Paperstocks89 Aug. 19 at 3:58 PM

$KNSA how is this still sub $100

0 · Reply

findingthestock Aug. 11 at 3:13 AM

$ARDX Raab mismanagement has destroyed shareholders While other ceos are delivering $ARDX must learn an IR lesson from $KNSA on how to handle guidance. Regular beats & raises better than woolly long term goals & misses. Major difference in stock price trajectories & revenue multiples. IR is CEO level stuff. It is massively impactful.

1 · Reply

stockpicker63 Aug. 1 at 5:12 AM

Weekly trading performance on the site! Top trades $KC +12%, $BLKB +10% , $KNSA +9.8% seel al trades on the site.

0 · Reply

Jaylan1 Jul. 29 at 6:24 PM

$KNSA enough with the run

1 · Reply

Quantumup Jul. 29 at 2:02 PM

Wedbush⬆️ $KNSA's PT to $99 from $72 and reiterated at Outperform after KNSA reported positive recurrent pericarditis (RP) data for KPL-387 alongside a strong quarter. $CRDL VTYX - $LLY REGN NVS Wedbush continues to view KPL-387 as an important and de-risked life-cycle extension opportunity, w/ potential to reinforce KNSA's leadership in IL-1 blockade in RP while materially improving the long-term economic profile of the franchise.

0 · Reply

topstockalerts Jul. 29 at 2:22 AM

$KNSA this is holding way too well to ignore

0 · Reply

RTPRwire Jul. 28 at 9:31 PM

Today's biggest catalyst moves on the wire: $ONFO +54% M&A / acquisition $APUS +35% product launch $VRRM +27% contract win $KNSA +27% clinical trial results Get real-time catalyst alerts using RTPR.

0 · Reply

BDE_Worldwide Jul. 28 at 7:42 PM

$KNSA BEAST.

0 · Reply

MaverikIT Jul. 28 at 7:27 PM

@Jblack500 @cynicaloptimist @BustaCapital @IsabellaDC @WAJeff @No_Face_character $KNSA nice

0 · Reply

Avocado_smash Jul. 28 at 6:54 PM

$KNSA wow 😮

0 · Reply

Kiniksa Pharmaceuticals International, Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 7, 2026, 4:01 PM EDT - 11 days ago

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

2026-07-30T10:17:03.000Z - 20 days ago

Kiniksa price target raised to $90 from $75 at Goldman Sachs

2026-07-29T13:05:25.000Z - 21 days ago

Kiniksa price target raised to $99 from $72 at Wedbush

2026-07-29T12:03:41.000Z - 21 days ago

Kiniksa price target raised to $107 from $72 at JPMorgan

2026-07-29T11:21:40.000Z - 21 days ago

Kiniksa price target raised to $98 from $64 at Canaccord

2026-07-29T10:31:31.000Z - 21 days ago

Kiniksa price target raised to $100 from $60 at Citi

2026-07-28T16:05:56.000Z - 22 days ago

Kiniksa rises 23.9%

2026-07-28T14:05:53.000Z - 22 days ago

Kiniksa rises 22.7%

Jul 28, 2026, 8:30 AM EDT - 22 days ago

Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q2 2026

Jul 28, 2026, 8:30 AM EDT - 22 days ago

Kiniksa Pharmaceuticals International, Earnings release: Q2 2026

Jul 28, 2026, 8:30 AM EDT - 22 days ago

Kiniksa Pharmaceuticals International, Slides: Q2 2026

Jul 28, 2026, 8:30 AM EDT - 22 days ago

Kiniksa Pharmaceuticals International, Quarterly report: Q2 2026

2026-07-28T11:45:31.000Z - 22 days ago

Kiniksa reports Q2 EPS 30c, consensus 28c

2026-07-28T11:45:26.000Z - 22 days ago

Kiniksa raises FY26 revenue view to $980M-$995M from $930M-$945M

Jul 28, 2026, 7:30 AM EDT - 22 days ago

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

Jul 23, 2026, 4:01 PM EDT - 26 days ago

Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026

2026-07-23T10:06:16.000Z - 27 days ago

Kiniksa price target raised to $75 from $60 at Goldman Sachs

2026-07-13T10:30:56.000Z - 5 weeks ago

Kiniksa price target raised to $74 from $57 at Wells Fargo

2026-06-29T11:55:18.000Z - 7 weeks ago

Kiniksa price target raised to $72 from $59 at Wedbush

Jun 9, 2026, 11:20 AM EDT - 2 months ago

Kiniksa Pharmaceuticals International, Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 8:45 AM EDT - 2 months ago

Kiniksa Pharmaceuticals International, Transcript: Jefferies Global Healthcare Conference 2026

May 29, 2026, 4:01 PM EDT - 2 months ago

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

2026-04-29T12:53:44.000Z - 4 months ago

Kiniksa price target raised to $64 from $62 at Canaccord

2026-04-29T12:23:45.000Z - 4 months ago

Kiniksa price target raised to $59 from $58 at Wedbush

2026-04-29T11:00:19.000Z - 4 months ago

Kiniksa price target raised to $60 from $50 at Citi

2026-04-28T17:07:23.000Z - 4 months ago

Kiniksa price target raised to $71 from $58 at Jefferies

2026-04-28T16:06:33.000Z - 4 months ago

Kiniksa rises 19.3%

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q1 2026

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Kiniksa Pharmaceuticals International, Earnings release: Q1 2026

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Kiniksa Pharmaceuticals International, Slides: Q1 2026

Apr 28, 2026, 8:30 AM EDT - 4 months ago

Kiniksa Pharmaceuticals International, Quarterly report: Q1 2026

Apr 28, 2026, 7:30 AM EDT - 4 months ago

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Apr 23, 2026, 4:01 PM EDT - 4 months ago

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Kiniksa Pharmaceuticals International, Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Kiniksa Pharmaceuticals International, Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 4 months ago

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

Mar 2, 2026, 3:10 PM EST - 6 months ago